DSM Biologics forms biotech collaboration with Crucell
Biopharma custom manufacturer DSM Biologics has entered into a collaboration agreement with Crucell. The objective will be the further development and production of biopharmaceutical products such as recombinant proteins and monoclonal antibodies. DSM Biologics will contribute production expertise and process optimisation capabilities, while Crucell brings unique know-how in the form of the PER.C6 cell line and technology, which form the basis for achieving the required high productivity.
DSM Biologics will obtain, against payment, a licence on the technology, entitling it to grant sub-licences to third parties for the development and preparation of the biopharmaceutical proteins.